ACRV Stock Summary and Trading Ideas (Acrivon Therapeutics | NASDAQ:ACRV)

Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.

Acrivon Therapeutics trades on the NASDAQ stock market under the symbol ACRV.

As of January 29, 2025, ACRV stock price was flat at $5.55 with 14,353 million shares trading.

ACRV has a beta of 1.24, meaning it tends to be more sensitive to market movements. ACRV has a correlation of 0.03 to the broad based SPY ETF.

ACRV has a market cap of $172.81 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that ACRV belongs to (by Net Assets): VTI, IWM, VXF, IBB, IWN.

ACRV has outperformed the market in the last year with a return of +45.3%, while the SPY ETF gained +24.9%. However, in the most recent history, ACRV shares have underperformed the stock market with its stock returning -32.1% in the last 3 month period and -0.2% for the last 2 week period, while SPY has returned +4.0% and +3.4%, respectively.

ACRV support price is $5.19 and resistance is $5.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ACRV shares will trade within this expected range on the day.